Muehlbacher M, Nickel MK, Nickel C; m.fl. (2005). «Mirtazapine reduces social anxiety and improves quality of life in women with social phobia». J Clin Psychopharmacol. 25 (6): 580–583. PMID16282842. doi:10.1097/01.jcp.0000186871.04984.8d.CS1-vedlikehold: Eksplisitt bruk av m.fl. (link)CS1-vedlikehold: Flere navn: forfatterliste (link)
Rocha FL, Vorcaro CM, Uchoa E, Lima-Costa MF (2005). «Comparing the prevalence rates of social phobia in a community according to ICD-10 and DSM-III-R». Rev Bras Psiquiatr. 27 (3): 222–4. PMID16224610. doi:/S1516-44462005000400011 (inaktiv 2010-03-19) Sjekk |doi=-verdien (hjelp).CS1-vedlikehold: Flere navn: forfatterliste (link)
Westenberg, HG. (1999). «Facing the challenge of social anxiety disorder.». Eur Neuropsychopharmacol. 9 Suppl 3: S93–9. PMID10523064.
Muehlbacher M, Nickel MK, Nickel C; m.fl. (2005). «Mirtazapine reduces social anxiety and improves quality of life in women with social phobia». J Clin Psychopharmacol. 25 (6): 580–583. PMID16282842. doi:10.1097/01.jcp.0000186871.04984.8d.CS1-vedlikehold: Eksplisitt bruk av m.fl. (link)CS1-vedlikehold: Flere navn: forfatterliste (link)
[94] ^ Murray B. Stein, MD; Jack M. Gorman, MD. Journal of Psychiatry & Neuroscience Volume 26. Unmasking social anxiety disorder 2001. Hentet 01.03.2006.